Collegium Pharmaceutical Inc
NASDAQ:COLL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Collegium Pharmaceutical Inc
Other Non-Cash Items
Collegium Pharmaceutical Inc
Other Non-Cash Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Collegium Pharmaceutical Inc
NASDAQ:COLL
|
Other Non-Cash Items
$62.3m
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
40%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Non-Cash Items
$1.4B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Non-Cash Items
$4.5B
|
CAGR 3-Years
47%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
14%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Non-Cash Items
$4.8B
|
CAGR 3-Years
68%
|
CAGR 5-Years
23%
|
CAGR 10-Years
10%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Non-Cash Items
$1B
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Non-Cash Items
$4B
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
15%
|
|
Collegium Pharmaceutical Inc
Glance View
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The company is headquartered in Stoughton, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2015-05-07. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The firm's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
See Also
What is Collegium Pharmaceutical Inc's Other Non-Cash Items?
Other Non-Cash Items
62.3m
USD
Based on the financial report for Dec 31, 2025, Collegium Pharmaceutical Inc's Other Non-Cash Items amounts to 62.3m USD.
What is Collegium Pharmaceutical Inc's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 10Y
40%
Over the last year, the Other Non-Cash Items growth was 29%. The average annual Other Non-Cash Items growth rates for Collegium Pharmaceutical Inc have been 20% over the past three years , 15% over the past five years , and 40% over the past ten years .
